Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes

2002 ◽  
Vol 19 (8) ◽  
pp. 685-688 ◽  
Author(s):  
J. M. M. Evans ◽  
P. T. Donnan ◽  
A. D. Morris
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Oral Hypoglycaemic Agents ◽  
Hypoglycaemic Agents

scholarly journals Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

2009 ◽  
Vol 161 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Bianca Hemmingsen ◽  
Søren S Lund ◽  
Jørn Wetterslev ◽  
Allan Vaag
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Meta Analysis ◽  
Current Evidence ◽  
Cvd Risk ◽  
Oral Hypoglycaemic Agents ◽  
Increase Insulin Sensitivity ◽  
Hypoglycaemic Agents ◽  
Conflicting Evidence

This article is a narrative review of the current evidence of the effects on cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, metformin has been demonstrated to reduce CVD risk, and this beneficial effect may be conserved with the combination of metformin and insulin treatment. However, the effect of glitazones on CVD is uncertain. There is conflicting evidence from large randomized trials to support a protective effect against CVD of lowering blood glucose per se but a systematic review with meta-analysis is lacking. It may be reasonable to aim for an intervention targeting multiple CVD risk factors such as dyslipidaemia, hypertension and albuminuria in T2D patients.

Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus

2013 ◽  
Vol 16 (3) ◽  
pp. 276-283 ◽  
Author(s):  
G. E. C. Sun ◽  
B. J. Wells ◽  
K. Yip ◽  
R. Zimmerman ◽  
D. Raghavan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cancer Risk ◽  
Oral Hypoglycaemic Agents ◽  
Hypoglycaemic Agents ◽  
Specific Effects ◽  
Gender Specific
Sign in / Sign up

Export Citation Format

Share Document